Yungjin Pharm. Co., Ltd. (003520.KS)
KRW 1989.0
(-2.02%)
KRW 1989.0
(-2.02%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 66.88 Billion KRW | 70.09% |
| 2022 | 39.32 Billion KRW | 201.1% |
| 2021 | 13.05 Billion KRW | 79.32% |
| 2020 | 7.28 Billion KRW | -50.22% |
| 2019 | 14.62 Billion KRW | 19.01% |
| 2018 | 12.29 Billion KRW | -32.31% |
| 2017 | 18.15 Billion KRW | -19.56% |
| 2016 | 22.57 Billion KRW | -16.19% |
| 2015 | 26.93 Billion KRW | 42.6% |
| 2014 | 18.89 Billion KRW | -7.14% |
| 2013 | 20.34 Billion KRW | -18.36% |
| 2012 | 24.91 Billion KRW | -10.5% |
| 2011 | 27.83 Billion KRW | 15.78% |
| 2010 | 24.04 Billion KRW | -48.92% |
| 2009 | 47.07 Billion KRW | 30.73% |
| 2008 | 36.01 Billion KRW | -8.33% |
| 2007 | 39.28 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 65.98 Billion KRW | -0.6% |
| 2024 Q1 | 66.38 Billion KRW | -0.74% |
| 2023 Q1 | 45.46 Billion KRW | 15.63% |
| 2023 Q3 | 56.42 Billion KRW | 22.23% |
| 2023 Q2 | 46.16 Billion KRW | 1.54% |
| 2023 FY | 66.88 Billion KRW | 70.09% |
| 2023 Q4 | 66.88 Billion KRW | 18.52% |
| 2022 Q1 | 29.32 Billion KRW | 124.56% |
| 2022 Q2 | 25.48 Billion KRW | -13.08% |
| 2022 Q3 | 28.67 Billion KRW | 12.51% |
| 2022 Q4 | 39.32 Billion KRW | 37.11% |
| 2022 FY | 39.32 Billion KRW | 201.1% |
| 2021 FY | 13.05 Billion KRW | 79.32% |
| 2021 Q1 | 10.55 Billion KRW | 44.9% |
| 2021 Q2 | 11.59 Billion KRW | 9.84% |
| 2021 Q3 | 7.3 Billion KRW | -37.02% |
| 2021 Q4 | 13.05 Billion KRW | 78.89% |
| 2020 Q3 | 12.6 Billion KRW | -17.97% |
| 2020 Q2 | 15.37 Billion KRW | 5.57% |
| 2020 Q1 | 14.56 Billion KRW | -0.47% |
| 2020 FY | 7.28 Billion KRW | -50.22% |
| 2020 Q4 | 7.28 Billion KRW | -42.24% |
| 2019 Q2 | 18.98 Billion KRW | 8.94% |
| 2019 Q3 | 9.69 Billion KRW | -48.94% |
| 2019 Q4 | 14.62 Billion KRW | 50.87% |
| 2019 FY | 14.62 Billion KRW | 19.01% |
| 2019 Q1 | 17.43 Billion KRW | 41.81% |
| 2018 Q2 | 14.17 Billion KRW | 18.95% |
| 2018 Q4 | 12.29 Billion KRW | -22.37% |
| 2018 FY | 12.29 Billion KRW | -32.31% |
| 2018 Q1 | 11.91 Billion KRW | -34.37% |
| 2018 Q3 | 15.83 Billion KRW | 11.7% |
| 2017 Q3 | 14.5 Billion KRW | -30.95% |
| 2017 Q4 | 18.15 Billion KRW | 25.23% |
| 2017 FY | 18.15 Billion KRW | -19.56% |
| 2017 Q1 | 22 Billion KRW | -2.55% |
| 2017 Q2 | 21 Billion KRW | -4.55% |
| 2016 Q4 | 22.57 Billion KRW | -13.61% |
| 2016 FY | 22.57 Billion KRW | -16.19% |
| 2016 Q3 | 26.13 Billion KRW | -3.06% |
| 2016 Q2 | 26.95 Billion KRW | 1.16% |
| 2016 Q1 | 26.64 Billion KRW | -1.08% |
| 2015 Q2 | 28.69 Billion KRW | 10.46% |
| 2015 Q4 | 26.93 Billion KRW | -17.94% |
| 2015 Q3 | 32.82 Billion KRW | 14.41% |
| 2015 Q1 | 25.97 Billion KRW | 37.5% |
| 2015 FY | 26.93 Billion KRW | 42.6% |
| 2014 Q1 | 16.78 Billion KRW | -17.48% |
| 2014 Q2 | 19.73 Billion KRW | 17.54% |
| 2014 FY | 18.89 Billion KRW | -7.14% |
| 2014 Q4 | 18.89 Billion KRW | -10.29% |
| 2014 Q3 | 21.05 Billion KRW | 6.72% |
| 2013 Q3 | 28.05 Billion KRW | -8.51% |
| 2013 Q4 | 20.34 Billion KRW | -27.5% |
| 2013 Q2 | 30.67 Billion KRW | 24.04% |
| 2013 FY | 20.34 Billion KRW | -18.36% |
| 2013 Q1 | 24.72 Billion KRW | -0.77% |
| 2012 FY | 24.91 Billion KRW | -10.5% |
| 2012 Q4 | 24.91 Billion KRW | -11.99% |
| 2012 Q3 | 28.31 Billion KRW | -3.52% |
| 2012 Q2 | 29.34 Billion KRW | 6.82% |
| 2012 Q1 | 27.46 Billion KRW | -1.33% |
| 2011 FY | 27.83 Billion KRW | 15.78% |
| 2011 Q2 | 20.29 Billion KRW | -7.42% |
| 2011 Q1 | 21.91 Billion KRW | -8.85% |
| 2011 Q4 | 27.83 Billion KRW | 28.5% |
| 2011 Q3 | 21.66 Billion KRW | 6.77% |
| 2010 Q1 | 47.37 Billion KRW | 0.63% |
| 2010 Q4 | 24.04 Billion KRW | -25.07% |
| 2010 Q3 | 32.08 Billion KRW | -30.82% |
| 2010 Q2 | 46.38 Billion KRW | -2.08% |
| 2010 FY | 24.04 Billion KRW | -48.92% |
| 2009 Q1 | 44.8 Billion KRW | 24.43% |
| 2009 Q4 | 47.07 Billion KRW | 14.28% |
| 2009 FY | 47.07 Billion KRW | 30.73% |
| 2009 Q2 | 42.12 Billion KRW | -5.99% |
| 2009 Q3 | 41.19 Billion KRW | -2.2% |
| 2008 Q2 | 36.89 Billion KRW | -2.82% |
| 2008 Q4 | 36.01 Billion KRW | -2.21% |
| 2008 FY | 36.01 Billion KRW | -8.33% |
| 2008 Q3 | 36.82 Billion KRW | -0.19% |
| 2008 Q1 | 37.96 Billion KRW | -3.35% |
| 2007 Q1 | 84.11 Billion KRW | 0.0% |
| 2007 Q4 | 39.28 Billion KRW | -47.52% |
| 2007 Q3 | 74.84 Billion KRW | -1.22% |
| 2007 Q2 | 75.77 Billion KRW | -9.91% |
| 2007 FY | 39.28 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -69.721% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 90.333% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 82.494% |
| HANDOK Inc. | 300.01 Billion KRW | 77.707% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -118.126% |
| Yuhan Corporation | 230.07 Billion KRW | 70.93% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 83.555% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -11131.511% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 88.325% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -5082.527% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 21.463% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -54.559% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 26.083% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -152.071% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -69.721% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -27986.832% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 70.282% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 63.048% |
| JW Holdings Corporation | 554.58 Billion KRW | 87.94% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 69.298% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 69.566% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 60.722% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -44.919% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -70.596% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 61.973% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 21.283% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -69.721% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 71.617% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 85.76% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 60.722% |
| Yuhan Corporation | 230.07 Billion KRW | 70.93% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 61.347% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 85.705% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 60.722% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 43.625% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -65.8% |
| CKD Bio Corp. | 146.92 Billion KRW | 54.479% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 54.206% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -38.6% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -10482.175% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -44.919% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 85.71% |
| Boryung Corporation | 204.21 Billion KRW | 67.249% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 15.752% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 21.463% |
| JW Lifescience Corporation | 46.31 Billion KRW | -44.414% |